SAPHNELO 120mg 150mg / ml solution for injection in pre-filled pen medication leaflet

L04AG11 • anifrolumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Monoclonal antibodies

Anifrolumab is a monoclonal antibody used for the treatment of moderate to severe systemic lupus erythematosus (SLE). It works by blocking the type I interferon receptor, a cytokine involved in the inflammation and immune system activation characteristic of lupus. By inhibiting this receptor, anifrolumab reduces disease activity and associated symptoms.

Anifrolumab is administered intravenously, usually once a month, and is particularly indicated for patients who do not respond adequately to conventional therapies.

Common side effects include upper respiratory tract infections, headaches, nausea, and injection site reactions. In rare cases, severe adverse reactions such as serious infections or hypersensitivity may occur.

Patients receiving anifrolumab should undergo regular monitoring for signs of infection and treatment efficacy. The medication represents a promising option for managing systemic lupus erythematosus, helping to improve the quality of life for patients with this chronic condition.